Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24
Calidi Biotherapeutics (NYSE American: CLDI) announces an exclusive live investor webinar scheduled for April 24, 2025, at 4:15 p.m. ET. The event will feature presentations by newly appointed Chief Medical Officer Dr. Guy Travis Clifton and CFO Andrew Jackson.
Dr. Clifton, a surgical oncologist and U.S. Army Colonel with 17 years of experience in oncology drug development, will discuss Calidi's stem cell-based delivery platforms for enhanced cancer treatment. The webinar will highlight the company's progression following FDA clearance of their IND application for CLD-201, an allogeneic stem cell-based immunotherapy for solid tumors, focusing on breast cancer, head & neck cancer, and soft tissue sarcoma.
The presentation will also cover other lead programs including CLD-400 (RTNova) for metastatic and lung cancer, and CLD-101 for high-grade gliomas. A Q&A session will follow the presentation.
Calidi Biotherapeutics (NYSE American: CLDI) annuncia un webinar esclusivo per investitori in diretta, previsto per il 24 aprile 2025 alle 16:15 ET. L'evento vedrà le presentazioni del neo nominato Chief Medical Officer, il Dr. Guy Travis Clifton, e del CFO Andrew Jackson.
Il Dr. Clifton, oncologo chirurgico e colonnello dell'esercito statunitense con 17 anni di esperienza nello sviluppo di farmaci oncologici, illustrerà le piattaforme di somministrazione basate su cellule staminali di Calidi per migliorare il trattamento del cancro. Il webinar metterà in evidenza i progressi dell'azienda dopo l'approvazione FDA della loro domanda IND per CLD-201, un'immunoterapia allogenica basata su cellule staminali per tumori solidi, con particolare attenzione a tumore al seno, testa e collo e sarcoma dei tessuti molli.
La presentazione includerà anche altri programmi principali, tra cui CLD-400 (RTNova) per cancro metastatico e polmonare, e CLD-101 per glioma di alto grado. Seguirà una sessione di domande e risposte.
Calidi Biotherapeutics (NYSE American: CLDI) anuncia un seminario web exclusivo en vivo para inversores programado para el 24 de abril de 2025 a las 4:15 p.m. ET. El evento contará con presentaciones del recientemente nombrado Director Médico, Dr. Guy Travis Clifton, y del CFO Andrew Jackson.
El Dr. Clifton, oncólogo quirúrgico y coronel del ejército de EE.UU. con 17 años de experiencia en desarrollo de fármacos oncológicos, hablará sobre las plataformas de administración basadas en células madre de Calidi para mejorar el tratamiento del cáncer. El seminario destacará el progreso de la compañía tras la aprobación de la FDA de su solicitud IND para CLD-201, una inmunoterapia alogénica basada en células madre para tumores sólidos, enfocándose en cáncer de mama, cabeza y cuello, y sarcoma de tejidos blandos.
La presentación también cubrirá otros programas principales, incluyendo CLD-400 (RTNova) para cáncer metastásico y de pulmón, y CLD-101 para gliomas de alto grado. Después de la presentación habrá una sesión de preguntas y respuestas.
Calidi Biotherapeutics (NYSE American: CLDI)는 2025년 4월 24일 오후 4시 15분(동부시간)에 독점 라이브 투자자 웨비나를 개최한다고 발표했습니다. 이번 행사에는 새로 임명된 최고 의료 책임자(Chief Medical Officer) Dr. Guy Travis Clifton과 CFO Andrew Jackson의 발표가 포함됩니다.
외과 종양 전문의이자 미 육군 대령인 Dr. Clifton은 17년간의 종양학 약물 개발 경험을 바탕으로 암 치료를 향상시키기 위한 Calidi의 줄기세포 기반 전달 플랫폼에 대해 설명할 예정입니다. 웨비나에서는 고형암을 위한 동종 줄기세포 기반 면역치료제 CLD-201의 IND 신청에 대한 FDA 승인 이후 회사의 발전 상황을 강조하며, 유방암, 두경부암, 연부조직 육종에 중점을 둡니다.
발표는 전이성 및 폐암 치료를 위한 CLD-400 (RTNova)와 고등급 교모세포종 치료제 CLD-101 등 다른 주요 프로그램도 다룰 예정입니다. 발표 후 질의응답 시간이 이어집니다.
Calidi Biotherapeutics (NYSE American : CLDI) annonce un webinaire exclusif en direct pour les investisseurs, prévu le 24 avril 2025 à 16h15 ET. L'événement comprendra des présentations du nouveau Chief Medical Officer, le Dr Guy Travis Clifton, et du CFO Andrew Jackson.
Le Dr Clifton, oncologue chirurgical et colonel de l'armée américaine avec 17 ans d'expérience dans le développement de médicaments oncologiques, présentera les plateformes de délivrance basées sur les cellules souches de Calidi pour améliorer le traitement du cancer. Le webinaire mettra en lumière les progrès de la société suite à l'autorisation de la FDA de leur demande IND pour CLD-201, une immunothérapie allogénique basée sur les cellules souches pour les tumeurs solides, en se concentrant sur le cancer du sein, de la tête et du cou, ainsi que sur le sarcome des tissus mous.
La présentation couvrira également d'autres programmes phares, dont CLD-400 (RTNova) pour les cancers métastatiques et du poumon, ainsi que CLD-101 pour les gliomes de haut grade. Une session de questions-réponses suivra la présentation.
Calidi Biotherapeutics (NYSE American: CLDI) kündigt ein exklusives Live-Webinar für Investoren an, das am 24. April 2025 um 16:15 Uhr ET stattfindet. Die Veranstaltung beinhaltet Präsentationen des neu ernannten Chief Medical Officers Dr. Guy Travis Clifton und des CFO Andrew Jackson.
Dr. Clifton, ein chirurgischer Onkologe und Oberst der US-Armee mit 17 Jahren Erfahrung in der Entwicklung von Onkologika, wird Calidis auf Stammzellen basierende Lieferplattformen zur verbesserten Krebsbehandlung vorstellen. Das Webinar wird den Fortschritt des Unternehmens nach der FDA-Freigabe ihres IND-Antrags für CLD-201 hervorheben, einer allogenen, auf Stammzellen basierenden Immuntherapie für solide Tumore, mit Fokus auf Brustkrebs, Kopf-Hals-Krebs und Weichteilsarkome.
Die Präsentation umfasst auch weitere führende Programme, darunter CLD-400 (RTNova) für metastasierten und Lungenkrebs sowie CLD-101 für hochgradige Gliome. Im Anschluss folgt eine Fragerunde.
- FDA clearance received for CLD-201 IND application
- Appointment of experienced CMO with 17 years of oncology expertise
- Multiple pipeline programs targeting various cancer types
- None.
SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a webinar on April 24, 2025, at 4:15 p.m. ET.
The exclusive event, hosted by RedChip Companies, will feature Calidi’s newly appointed Chief Medical Officer, Consultant and Advisor, Guy Travis Clifton, MD, who will share insight into the company’s groundbreaking stem cell-based delivery platforms designed to protect, amplify, and potentiate oncolytic viruses for enhanced cancer treatment. Dr. Clifton will be joined by Calidi’s CFO Andrew Jackson.
Dr. Clifton, a practicing surgical oncologist and U.S. Army Colonel, brings over 17 years of experience in oncology drug development, early-phase trials, and cancer immunotherapy. His appointment marks a significant addition to Calidi’s leadership team as the company advances into its next phase of clinical development following the U.S. Food and Drug Administration clearance of Calidi’s Investigation New Drug application for CLD-201. This investigational, allogeneic stem cell-based immunotherapy is set to advance into clinical development for the treatment of solid tumors in adults, focusing on breast cancer, head & neck cancer and soft tissue sarcoma.
Highlights of the webinar will also include overviews of Calidi’s other lead programs, such as CLD-400 or RTNova, a systemic platform targeting metastatic and lung cancer and CLD-101, designed to treat high-grade gliomas. A live Q&A session with the leadership team will follow the presentation.
To register for the free webinar, please visit: https://redchip.zoom.us/webinar/register/WN_fAqVv5c4RTaBaQ3s4WEaRA
Questions can be pre-submitted to CLDI@redchip.com or online during the live event.
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies, are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.
Forward-Looking Statements
This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning upcoming key milestones (including the reporting of interim clinical results and the dosing of patients), planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Registration Statements filed with the SEC on (i) Form S-4 filed on August 2, 2023 and the corresponding prospectus filed on August 4, 2023, and (ii) on Form S-1 filed on April 15, 2024, and the Company’s periodic report filed with the SEC on Form 10-K filed on March 31, 2025. These reports may be amended or supplemented by other reports we file with the SEC from time to time.
Corporate Communications:
Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
CLDI@redchip.com
Source: Calidi Biotherapeutics, Inc.
FAQ
What is the focus of Calidi Biotherapeutics' (CLDI) upcoming investor webinar on April 24, 2025?
What are the target indications for Calidi's (CLDI) CLD-201 immunotherapy program?
What recent FDA milestone has Calidi Biotherapeutics (CLDI) achieved for CLD-201?
What cancer types does Calidi's (CLDI) CLD-400 (RTNova) platform target?
